Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$53.83 USD
-0.03 (-0.06%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $53.80 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PTGX 53.83 -0.03(-0.06%)
Will PTGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTGX
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Insider Sell: PATEL DINESH V PH D Sells Shares of Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc (PTGX) Submits NDA for Icotrokinra to FDA | PTGX stock news
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra